On April 4, Terence Rice, Vice President & Chief Information Security Officer (CISO) at Merck & Co., Inc. presented a concern to the Subcommittee on Oversight and Investigations of the House Committee on Energy and Commerce-he stated that cybersecurity in the healthcare industry is much worse than is narrated. He suggested that solutions will require a transparent partnership of both public and private.
Rice cited the 2016 IBM Cyber Security Intelligence Index, which reports the healthcare industry as the most attacked industry, with reasons on why risks to the industry are understated in media reports. He believes that organizational concerns about reputational damage, the inadequate resources of smaller businesses, the transferability of healthcare information, and the abundance of software for healthcare are all factors in cybersecurity risks.
He is confident, however, that with initiatives that are already put in place-the Department of Health & Human Services Sector Coordinating Council; NH-ISAC, an alliance of more than 200 companies in the industry; and SAFE-BioPharma Association-plus additional opportunities for collaboration, the enhancement of a greater healthcare cybersecurity is possible.
To read Rice’s full testimony and learn more about his recommended additional opportunities, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.